Savara Inc (FRA:YB4P)
€ 3 -0.12 (-3.85%) Market Cap: 518.72 Mil Enterprise Value: 333.79 Mil PE Ratio: 0 PB Ratio: 2.70 GF Score: 31/100

Savara Inc at Guggenheim Healthcare Talks Biotechnology Conference Transcript

Feb 07, 2024 / 04:30PM GMT
Release Date Price: €4.34
Vamil Divan
Guggenheim Securities, LLC - Analyst

I think we're ready to get started here. Thanks so much, everyone, again for joining us for our Annual Biotech Conference. I'm Vamil Divan, one of the biopharma analyst here at Guggenheim. Happy to have our next company here at Savara, a company we actually just recently launched coverage on a few months back.

We have Matt Pauls, the CEO; Ray Pratt, the CMO; we also have, Anne Erickson, Chief Business Officer in the back. (Conference Instructions)

But I thought maybe I'll just start with you. And just giving up for those people that may be less familiar with the story, a little bit of background in Savara, and some of the key recent events, obviously there's a big data readout coming up here, which we'll talk about that, but the path to get us to this point we're hopeful this will kick things off.

Questions & Answers

Matthew Pauls
Savara Inc - President, Chief Executive Officer

Yaah sure. So I'm Matt Pauls, Chair of the Board of Directors, and CEO of Savara. Thanks for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot